SCHEMBL27118019

SCHEMBL27118019

COc1cccc(-c2ccc(S(=O)(=O)Nc3cccc4cnn(C)c34)cn2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGES2 Q9H7Z7 2/20 0.43
▸ EIF2AK3 Q9NZJ5 2/20 0.43
▸ SLC40A1 Q9NP59 9/20 0.40
▸ GLO1 Q04760 3/20 0.40
▸ LMNA P02545 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ APLNR P35414 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ MITF O75030 1/20 0.35
▸ S1PR4 O95977 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ AGTR1 P30556 1/20 0.35
▸ OPRK1 P41145 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CKS1B P61024 1/20 0.35
▸ SKP2 Q13309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30846311 1.00 PTGES2 (0.43) PTGES2EIF2AK3SLC40A1GLO1LMNA
SCHEMBL27119198 0.87 EIF2AK3 (0.48) PTGES2EIF2AK3SLC40A1GLO1LMNA
SCHEMBL30846255 0.87 EIF2AK3 (0.48) PTGES2EIF2AK3SLC40A1GLO1LMNA
SCHEMBL27123171 0.87 EIF2AK3 (0.41) PTGES2EIF2AK3SLC40A1GLO1LMNA
SCHEMBL27118385 0.85 SLC40A1 (0.44) SLC40A1GLO1LMNAKMT2AMEN1
SCHEMBL27117884 0.82 SLC40A1 (0.39) SLC40A1GLO1LMNAMAPK1KMT2A
SCHEMBL30846273 0.82 GHSR (0.40) EIF2AK3SLC40A1GLO1LMNAMAPK1
SCHEMBL27119553 0.82 GHSR (0.40) EIF2AK3SLC40A1GLO1LMNAMAPK1
SCHEMBL30846320 0.82 SLC40A1 (0.44) PTGES2EIF2AK3SLC40A1GLO1LMNA
SCHEMBL27118281 0.82 SLC40A1 (0.44) PTGES2EIF2AK3SLC40A1GLO1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B PTGES2 2085/4885EIF2AK3 4041/4885SLC40A1 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback